Chemoradiation or Brachytherapy for Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: capecitabine and IMRT (if randomized to this arm)
Radiation: Endo-HDR (if randomized to this arm)
Radiation: IMRT (intensity modulated radiation therapy)
Drug: FOLFOX6
Procedure: Surgery

Registration Number: NCT02017704

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary: This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).

Detailed Description: Locally advanced rectal carcinoma continues to be a major oncologic problem in the United States with approximately 40,000 new cases diagnosed in 2011. For stage II/III rectal carcinoma, adjuvant chemoradiation and total mesorectal excision (TME) represent the major treatment advances that have increased cure rates over the past 30 years.

In the setting of TME, a landmark phase III German trial of stage II/III rectal cancer patients established neoadjuvant 5FU-based chemoradiation (NCRT) as standard of care over the same regimen given post-operatively. The preoperative arm showed superior local control (6% vs. 13% p=0.006), a complete pathologic response of 8%, a higher rate of sphincter preservation and less grade 3 toxicity compared to post-operative treatment. However, disease-free and overall survival (76% versus 74%, respectively) were no different because of the high rate of distant metastasis occurring in over 1/3 of patients (5yr DM 36 vs 38%,p=0.84). Importantly, those attaining a pathologic complete response had a decreased rate of distant metastasis and improved disease-free survival. Drawbacks to the regimen include acute grade 3 or 4 toxicity in 27% of patients, low compliance rates with postoperative chemotherapy (27 - 50%), and an overall decline in anorectal function shown by long-term studies.

Given the excellent locoregional control reported in TME surgical series, several trials have investigated whether certain patients may be spared preoperative radiotherapy. Two large randomized trials by Dutch and British investigators showed that a short preoperative course of hypofractionated EBRT (25 Gy in 5 fractions) followed by TME surgery decreased locoregional recurrence by 2/3 as compared to patients treated with TME surgery alone. In the Dutch trial, patients with mid and distal rectal cancers were most likely to benefit from radiotherapy. In these patients, preoperative radiation was shown to decrease locoregional recurrence by 5-fold (10% to 2%); however, the hypofractionated preoperative EBRT regimen was associated with a significant increase in acute and chronic morbidity. Indeed, the Dutch study revealed that irradiated patients, when compared to surgery alone, had more perineal wound healing problems after abdominoperineal resection (29% vs. 19%), worsening deterioration of anal sphincter dysfunction, and more severe long-term effects related to sexual functioning both in males (p=0.004) and females (p\<0.002). Additionally, colleagues have reported a consistent negative impact on bowel function in those patients undergoing sphincter preservation. In reviewing the long-term data of the Swedish short course preoperative EBRT rectal cancer trial, Birgisson also reported a higher incidence of secondary tumors (9.5%) in patients treated with preoperative radiation when compared to patients having surgery alone (4.3%).

Modern approaches to address the risk of distant metastasis and poor compliance with adjuvant systemic chemotherapy (following NCRT) have incorporated newer effective chemotherapy agents earlier in the treatment protocol. For example, oxaliplatin has been one of the most widely studied agents as a result of its proven efficacy when combined with 5-fluorouracil and leucovorin (FOLFOX) both in the metastatic and adjuvant settings for colon cancer. Initial phase II studies with the addition of oxaliplatin to standard 5-FU based NCRT appeared to show improved pathologic complete response rates compared to standard NCRT. However, two phase III trials clearly show that the addition of oxaliplatin during 5FU-based NCRT does not significantly improve pathologic complete response, locoregional control, distant metastasis or survival but does increase acute grade 3-4 toxicity by two to three-fold.

One approach to limit toxicity from external beam radiotherapy is the use of intensity modulated radiation therapy (IMRT). IMRT can limit radiation dose to normal rectum (above and below the tumor) and surrounding organs at risk (OARs) such as bladder and sexual organs. IMRT utilizes multiple beams of radiation to treat the rectal tumor plus a margin and limits dose to OARs. While IMRT decreases radiation dose to normal structures, it requires an additional 2-3 cm margin for microscopic extension (clinical treatment volume=CTV), set-up error, and rectal motion (planning treatment volume=PTV). Furthermore, IMRT still requires 5-6 weeks of radiation with concurrent chemotherapy, is substantially more expensive than conformal radiation, and is especially prohibitive in countries where access to technology necessary for IMRT is limited. Based on the preliminary results of RTOG 0822 and others, it still remains to be determined whether IMRT confers a statistically significant improvement in pCR, toxicity rates and QOL relative to standard NCRT.

A novel approach to limit radiation toxicity is the use of high dose rate endorectal brachytherapy (Endo-HDR). Endo-HDR involves the placement of a silicon multicatheter applicator within the rectum to deliver large doses to the rectal tumor and mesorectum with rapid dose fall off to the surrounding organs. An Iridium 192 high dose rate brachytherapy source attached to a wire is inserted into each catheter to deliver a high dose of radiation therapy the tumor. High dose rate brachytherapy has been well established in various malignancies (prostate, uterine, sarcoma, head and neck) to escalate radiation dose to the tumor over a short period of time while sparing normal tissue. Compared with NCRT and IMRT, Endo-HDR delivers treatment internally to the tumor without having to pass through surrounding normal tissue and organs. It requires smaller margins (CTV/PTV=\~1 cm) on the tumor since the applicator is positioned under fiducial guidance over the tumor without need for a margin for organ motion allowing greater sparing of OARs. Furthermore, the area of the rectum exposed to high dose radiotherapy is surgically removed at the time of resection which further minimizes chronic toxicity. Important structures that may be spared include bone marrow, small bowel, bladder, the autonomic nerves, sexual organs, anal sphincter and skin. Considering that 1/3 of patients will develop metastases, limiting bone marrow toxicity may contribute to better compliance with systemic treatment and allow for a better treatment strategy to target systemic recurrence. Another distinct advantage of Endo-HDR is the shortened treatment time (1 versus 6 weeks). Endo-HDR therefore provides a major logistic advantage for patients who may benefit from neoadjuvant therapy but who are geographically distant from radiation centers, elderly, or medically infirmed.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 9

Inclusion Criteria

Confirmed adenocarcinoma of the rectum
Appropriate tumor staging and location
Patients should be suitable candidates for surgery and chemotherapy
ECOG/WHO performance status 0-1
Patients must be 18 years or older
No previous history of pelvic radiation
Patients must have acceptable organ and marrow function
Non pregnant, non-breast feeding females under active contraception
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

Evidence of distant metastatic disease
Evidence of sphincter invasion on MRI
Prior history of radiation to the pelvis
Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, DCIS, or other cancer from which the patient has been disease free for at least 3 years
Presence of multiple small bowel loops trapped within the immediate tumor bed (post hysterectomy or prostatectomy).
Use of any investigational agent within the 4 weeks preceding enrollment
Previous exposure to chemotherapy for rectal cancer
Uncontrolled intercurrent illness including but not limited to, ongoing or active infections (or infections requiring systemic treatment), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant and breastfeeding women are excluded, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately.
Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test.
Contraindication for safe MRI, implants, or other conditions that interfere with imaging required for the study (e.g., pacemaker or non-MRI compatible hip prostheses). Note: Subjects with bilateral hip implants are not eligible for the study. Subjects with a unilateral hip implant may be eligible assuming the implant is MRI compatible and does not present artifact on MRI in the areas of interest.
Subject is pacemaker dependent.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IMRT and Capecitabine	capecitabine and IMRT (if randomized to this arm)	Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection
IMRT and Capecitabine	FOLFOX6	Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection
IMRT and Capecitabine	Surgery	Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection
Endo-HDR	FOLFOX6	Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection
IMRT and Capecitabine	IMRT (intensity modulated radiation therapy)	Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection
Endo-HDR	Endo-HDR (if randomized to this arm)	Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection
Endo-HDR	Surgery	Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy Followed by: * Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion * 5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions * 5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus Cycle length: 14 days (2 weeks) Duration of treatment: 12 cycles Then: Surgical Resection

Primary Outcome Measures

Name	Time	Method
Number of Patients With Pathologic Complete Response	Up to 60 months	Pathologic complete response rate is reported as the number of patients who achieve pathologic complete response after the treatment for each arm. As per the NCCN guidelines, pathologic response is graded by the system recommended by the AJCC Cancer Staging Manual and CAP guidelines: * Complete response - no remaining viable cancer cells * Moderate response - only small clusters/single cancer cells remain * Minimal response - residual cancer remaining, but with predominant fibrosis * Poor response - minimal/no tumor kills, extensive residual cancer

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Grade 3 or Higher Adverse Events	Up to 60 months	Number of participants with grade 3 or higher adverse events will be listed by relationship. Grading is by CTCAE 4 guidelines. Relationship, as determined by PI, is unrelated/unlikely/possible/probable/definite.
Time to Distant Metastases Free Survival	Up to 60 months	Compare distant metastasis for both Endo-HDR and CRT.
Change in EORTC QLQ-C30 Global Health Status Score	baseline, preop, postop, and at follow ups Y1-5	Patients were given the EORTC QLQ-C30 at baseline, preop, postop, and at follow ups Y1-5. The forms were scored as per the manual available at EORTC. Raw scores are transformed to fall in a range of 0-100. Generally, higher scores on QoL scales represent higher levels of QoL. The scores are reported as the mean of the Global Health Status/QoL scale score when more than 1 patient completed the form for a time point. If only 1 form was available for a time point, then the score for that form is reported.
Time to Progression Free Survival	Up to 60 months	Compare progression free survival for both Endo-HDR and CRT.
Time to Death	Up to 60 months	Assessing the difference time to death rates among study participants.
Time to Local Disease Recurrence	Up to 60 months	Compare locoregional control for both Endo-HDR and CRT.

Trial Locations

Locations (4): Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
The SKCCC at Johns Hopkins
🇺🇸
Baltimore, Maryland, United States
Winship Cancer Institute, Emory University
🇺🇸
Atlanta, Georgia, United States
Beth Israel Hospital
🇺🇸
New York, New York, United States